Meta-Analysis of the Efficacy and Safety of Imidafenacin for Overactive Bladder Induced by Benign Prostatic Hyperplasia in Men Receiving Alpha-Blocker Therapy

키워드

참고문헌 (38)

1. Bosch JL, "Natural history of benign prostatic hyperplasia : appropriate case definition and estimation of its prevalence in the community", Urology, 46(3 Suppl A), pp.34~40 (1995)
2. Boyle P, "The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study", BJU Int, 92, pp.409~414 (2003)
3. Witjes WP, "The International Continence Society"Benign Prostatic Hyperplasia"Study : international differences in lower urinary tract symptoms and related bother", J Urol, 157, pp.1295~1300 (1997)
4. Athanasopoulos A, "Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study", J Urol, 169, pp.2253~2256 (2003)
5. Lee KS, "Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction:a prospective, randomized, controlled multicenter study", J Urol, 174(4 Pt 1), pp.1334~1338 (2005)
6. Kaplan SA, "Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder : effects on urinary symptoms assessed by the International Prostate Symptom Score", BJU Int, 102, pp.1133~1139 (2008)
7. 배재현, "Efficacy and Safety of Low-Dose Propiverine in Patients with Lower Urinary Tract Symptoms", Benign Prostatic Hyperplasia with Storage Symptoms: A Prospective, Randomized, Single-Blinded and Multicenter Clinical Trial, 2011, pp.52(4), 274~278[DOI]
8. Yokoyama O, "Imidafenacin, an antimuscarinic agent, improves nocturia and reduces nocturnal urine volume", Urology, 82, pp.515~520 (2013)
9. Smith AL, "Outcomes of pharmacological management of nocturia with non-antidiuretic agents: does statistically significant equal clinically significant?", BJU Int, 107, pp.1550~1554 (2011)
10. Jacobsen SJ, "Natural history of prostatism : risk factors for acute urinary retention", J Urol, 158, pp.481~487 (1997)
11. Chapple CR, "The pathophysiological changes in the bladder obstructed by benign prostatic hyperplasia", Br J Urol, 73, pp.117~123 (1994)
12. Nishizawa O, "Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics", Low Urin Tract Symptoms, 3, pp.29~35 (2011)
13. Takeda M, "Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite α-blocker treatment in patients with BPH : the ADDITION study", Urology, 82, pp.887~893 (2013)
14. Gong M, "Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms : a meta-analysis", Curr Med Res Opin, 31, pp.1781~1792 (2015)
15. Vader JP, "Randomised controlled trials : A user’s guide", BMJ, 317, pp.1258~ (1998)
16. DerSimonian R, "Meta-analysis in clinical trials", Control Clin Trials, 7, pp.177~188 (1986)
17. Cho S, "A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent(imidafenacin)treatment in patients with lower urinary tract symptoms", benign prostatic hyperplasia and storage symptoms, 2017, 71~
18. Yokoyama O, "Add-on anticholinergic therapy for residual nocturia in patients with lower urinary tract symptoms receiving α1-blocker treatment: a multi-centre, prospective, randomised study", World J Urol, 33, pp.659~667 (2015)
19. Yankai Xu, "Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder", International Neurourology Journal, 21(3), pp.212~219 (2017), 대한배뇨장애요실금학회
20. Yamanishi T, "Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, open-label, controlled trial (DIrecT Study)", Int J Urol, 24, pp.525~531 (2017)
21. Kobayashi F, "Pharmacological effects of imidafenacin (KRP-197", ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task, 2007, pp.57, 147~154
22. Murakami S, "Pharmacological effects of KRP-197 on the human isolated urinary bladder", Urol Int, 71, pp.290~298 (2003)
23. Yamazaki T, "In vivo bladder selectivity of imidafenacin, a novel antimuscarinic agent, assessed by using an effectiveness index for bladder capacity in rats", Naunyn Schmiedebergs Arch Pharmacol, 384, pp.319~329 (2011)
24. Kawabe K, "Latest frontiers in pharmacotherapy for benign prostatic hyperplasia", Yakugaku Zasshi, 126(Spec no), pp.199~206 (2006)
25. Narayan P, "Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia", J Urol, 170(2 Pt 1), pp.498~502 (2003)
26. Lepor H, "Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia", Tamsulosin Investigator Group Urology, 51, pp.892~900 (1998)
27. Abrams P, "Tamsulosin, a selective alpha 1cadrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH). The European Tamsulosin Study Group", Br J Urol, 76, pp.325~336 (1995)
28. Yamaguchi O, "Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms--ASSIST, randomized controlled study", Urology, 78, pp.126~133 (2011)
29. Kaplan SA, "Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency", J Urol, 189(1 Suppl), pp.S129~S134 (2013)
30. Kaplan SA, "Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder : a randomized controlled trial", JAMA, 296, pp.2319~2328 (2006)
31. Chapple C, "Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers", Eur Urol, 56, pp.534~541 (2009)
32. Shi H, "The efficacy and safety of Vibegron in treating overactive bladder : A systematic review and pooled analysis of randomized controlled trials", Neurourol Urodyn, 39, pp.1255~1263 (2020)
33. Homma Y, "Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia", Int J Urol, 24, pp.716~729 (2017)
34. Wada N, "Effect of imidafenacin on nocturia and sleep disorder in patients with overactive bladder", Urol Int, 89, pp.215~221 (2012)
35. Matsuta Y, "Melatonin increases bladder capacity via GABAergic system and decreases urine volume in rats", J Urol, 184, pp.386~391 (2010)
36. Bunniran S, "A prospective study of elderly initiating mirabegron versus antimuscarinics : patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments", Neurourol Urodyn, 37, pp.177~185 (2018)
37. Andersson KE, "Antimuscarinics and the overactive detrusor--which is the main mechanism of action", Eur Urol, 43, pp.1~5 (2003)
38. Yamanishi T, "A 52-week multicenter randomized controlled study of the efficacy and safety of add-on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms(DIrecT study)", Low Urin Tract Symptoms, 11, pp.115~121 (2019)

관련 논문AI추천